ARMH1 is a novel marker associated with poor pediatric AML outcomes that affect the fatty acid synthesis and cell cycle pathways
2024

ARMH1: A New Marker for Poor Outcomes in Pediatric AML

Sample size: 21 publication 10 minutes Evidence: high

Author Information

Author(s): Bakhtiari Mojtaba, Jordan Sean C., Mumme Hope L., Sharma Richa, Shanmugam Mala, Bhasin Swati S., Bhasin Manoj

Primary Institution: Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, United States

Hypothesis

Is ARMH1 a significant biomarker associated with poor outcomes in pediatric acute myeloid leukemia (pAML)?

Conclusion

ARMH1 is associated with poor outcomes in pediatric AML and may serve as a potential target for therapy.

Supporting Evidence

  • ARMH1 expression is significantly elevated in blast cells of patients who relapsed or have a high-risk cytogenetic profile.
  • Knockdown of ARMH1 led to a significant reduction in cell proliferation and migration.
  • ARMH1 is correlated with a six-gene leukemia stem cell score associated with poor outcomes.
  • Pharmacological inhibition of CPT1A resulted in ARMH1 downregulation.

Takeaway

ARMH1 is a gene that can help doctors understand how serious a child's leukemia is and how to treat it better.

Methodology

The study analyzed bone marrow samples from 21 pediatric AML patients using single-cell RNA sequencing and functional assays to evaluate the impact of ARMH1 on cell proliferation and migration.

Limitations

The study lacks animal models to complement in vitro findings and has limited understanding of ARMH1's effects on immune cells.

Participant Demographics

Pediatric patients with acute myeloid leukemia.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.3389/fonc.2024.1445173

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication